819 results
Page 2 of 41
6-K
EX-99.2
28uh7qq
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.1
3hnbalcf zrn
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.1
bmbvwu0jl
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
6-K
EX-99.1
smbvewwsfhxiq 89kc
17 Jan 24
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
1:49pm
6-K
EX-99.1
2ez29ees3gktobh3obv
27 Dec 23
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
11:18am
6-K
EX-99.3
1e1ndljyt87
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.5
5zop6p60
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.4
dsy0lzcx
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
zgqtm8r3 zvx5hd
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.2
68p4zwuucm40
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
c5hh06j6phvt
1 Dec 23
Current report (foreign)
12:19pm
6-K
EX-99.1
6nz42alde2yg gm
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
6-K
EX-99.1
st8v vf0aav
27 Oct 23
Sanofi Enters Next Chapter of Play to Win Strategy
11:33am
6-K
EX-99.2
3bvhjo8z9h7wrvn
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.1
boo4szv146j2jsp7dej
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.1
7yz5ve2b78 97guih5
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.3
n5jni
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.2
qqtxyeugciolub20h
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.1
jc6 rh4r1ltciwg98n
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am
6-K
EX-99.2
mcq0aqle9foe0nn
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am